BY MARKETWIRE
-
WHO: Weight-loss drugs could help end obesity pandemic
Medicines have the potential to be transformative, says the World Well being Group’s chief scientist.
-
ALK enters Phase 2 after positive results for peanut allergy vaccine
A Stage 1/2 test revealed mainly moderate to modest and short-term adverse effects with ALK’s peanut allergic reaction vaccination prospect.
-
Eli Lilly’s Tirzepatide drugs removed from FDA shortage list
Currently in August, the United States drugmaker’s chief executive officer claimed the firm anticipated Tirzepatide to be gotten rid of from the scarcity listing.
-
MSD inks billion-dollar deal with Chinese biotech company for oral weight-loss drug
MSD is taking an action in the direction of the financially rewarding excessive weight market with the purchase of a prospect based upon the GLP-1 hormonal agent.
-
Novo Nordisk completes acquisition of three production facilities from Catalent transaction
With the purchase, Novo Nordisk has the ability to boost its ability to produce the prominent weight-loss medication Wegovy.
-
Demant secures loan agreement with NIB for EUR 100m
The lending arrangement is made following Tuesday’s statement of a comparable DKK 900m arrangement with the European Financial Investment Financial Institution.
-
ALK enters Phase 2 after positive results for peanut allergy vaccine
A Phase 1/2 trial showed mostly mild to moderate and transient side effects with ALK’s peanut allergy vaccine candidate.
-
Sonova gains ground from Demant and GN with US veterans
The Swiss business’s market share– determined by share of overall sales– enhanced in November to 51.5% from 48.8% in October.
-
Bavarian Nordic signs license and production deal with world’s largest vaccine maker
The contract is made to allow supply to the Indian market.
-
Novo Nordisk faces five key price drivers over the next year, says strategist
2 of the cost dives are supposedly unavoidable.
